Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

NCT06223711 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

RADIATION: Thoracic Radiochemotherapy
DRUG: durvalumab
RADIATION: Stereotactic radiotherapy of further tumor locations
DRUG: Chemotherapy

Sponsor

Universität des Saarlandes